Risk–benefit effects of tocolytic therapy

Bibliographys

• REPORT OF THE CONCENSUS DEVELOPMENT CONFERENCE ON THE EFFECT OF CORTICOSTEROIDS FOR FETAL MATURATION ON PERINATAL OUTCOMES. National Institutes of Health. N.I.H. Publication. (1994) Number 95:3784.
   Google Scholar
• PRYDE PG, BESINGER RE, GIANOPOULOS JG et al.: Adverse and beneficial effects of tocolytic therapy. Senna Perinatal (2001) 25:316–340.
   PubMed Web of Science ®Google Scholar
• MITTENDORF R, COVERT R,BOMAN J et al.: Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet (1997) 350:1517–1518.
   Google Scholar
• BENNETT P, EDWARDS D: Use of magnesium sulphate in obstetrics. Lancet (1997) 350:1491.
   PubMed Web of Science ®Google Scholar
• NELSON KB, GRETHER JK: Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics (1995) 95:263–269.
   PubMed Web of Science ®Google Scholar
• MITTENDORF R, COVERT R, ELIN R et al.: Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstet. Cyriecol. (2001) 98:75–78.
   Web of Science ®Google Scholar
• MITTENDORF R, DAMBROSIA J, PRYDE PG et al: Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am. Obstet. Cynecol. (2002) 186:1111–1118.
   PubMed Web of Science ®Google Scholar
• •The complete and "official" report detailing the adverse events in MagNET.
   Google Scholar
• CHESLEY LC: A survey of management and case mortality. In: Hypertensive disorders in pregnancy Chesley LC (Ed.), Appleton-Century-Crofts, New York (1978).
   Google Scholar
• MAHOMED K, GARNER P, DULEY L: Tocolytic magnesium sulphate and paediatric mortality. Lancet (1998) 351:293.
   PubMed Web of Science ®Google Scholar
• LUCAS MJ, LEVENO KJ, CUNNINGHAM FG: A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl. J. Med. (1995) 333:201–205.
   PubMed Web of Science ®Google Scholar
• •This, and the following reference, are excellently designed and conducted RCTs, and together provide the strongest possible evidence of the superiority of magnesium sulphate for seizure prophylaxis among pre-eclamptic women,
   Google Scholar
• THE ECLAMPSIA TRIAL COLLABORATIVE GROUP: Which anticonvulsant for women with eclampsia: evidence from the Collaborative Eclampsia Trial. Lancet (1995) 345:1455–1463.
   PubMed Web of Science ®Google Scholar
• THE MAGPIE TRIAL COLLABORATIVE GROUP: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomized placebo-controlled trial. Lancet (2002) 359:1877–1890.
   PubMed Web of Science ®Google Scholar
• BELFORT MA, ANTHONY J, SAADE GR et al.: Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl. J. Med. (2003) 348:304–311.
   PubMed Web of Science ®Google Scholar
• COTTON DB, STRASSNER HT, HILL LM et al: Comparison of magnesium sulfate, terbutaline, and a placebo for inhibition of preterm labor. A randomized study. J. Reprod. Med. (1984) 29:92–97.
   PubMed Web of Science ®Google Scholar
• COX SM, SHERMAN ML, LEVENO KJ: Randomized investigation of magnesium sulfate for prevention of preterm birth. Am.j Obstet. Cynecol. (1990) 163:767–772.
   PubMed Web of Science ®Google Scholar
• •Represents the best RCT of tocolytic magnesium versus placebo. It deserves careful attention because, contrary to widely accepted anecdotal impressions, and obstetrical dogma, it clearly showed the absence of tocolytic superiority of magnesium sulphate over saline placebo.
   Google Scholar
• FOX MD, ALBERT JR, MCCAUL JF et al: Neonatal morbidity between 34 and 37 weeks' gestation. J. Perinatol (1993) 13:349–353.
   PubMedGoogle Scholar
• HIGBY K, SUITE CR: A risk-benefit assessment of therapies for premature labour. Drug Sal (1999) 1:35–56.
   Web of Science ®Google Scholar
• HIGBY K, XENAKIS EM,PAUERSTEIN CJ: Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. km Obstet. Cynecol. (1993) 168:1247–1259.
   PubMed Web of Science ®Google Scholar
• GYETVAI K, HANNAH ME, HODNETT ED et al.: Tocolytics for preterm labor: a systematic review. Obstet. Cynecol. (1999) 94:869–877.
   Web of Science ®Google Scholar
• KEIRSE MJ, GRANT A, KING JF: Preterm labor. In: A guide to effective care in pregnancy and childbirth. Enkin M, Keirse MJ, Renfrew MJ, Neilson JP (Eds), Oxford University Press, Oxford, UK (1995):161–173.
   Google Scholar
• CROWTHER CA, HILLER JE, DOYLE LW: Magnesium sulphate for preventing preterm birth in threatened preterm labor. Cochrane Database of Systematic Reviews (2003) March.
   Google Scholar
• •In this systematic review, a comprehensive analysis of magnesium tocolysis data is performed, and it is concluded that magnesium sulphate is not an effective tocolytic and that high-dose magnesium appears to be harmful to the fetus.
   Google Scholar
• MITTENDORF R, PRYDE P, KHOSHNOOD B et al: If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact? Obstet. Cynecol. (1998) 92:308–311.
   Web of Science ®Google Scholar
• MITTENDORF R, DAMBROSIA J, DAMMANN 0 et al: Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. ./. Pediatr: (2002) 140:540–546.
   Google Scholar
• GAWAZ M, OTT I, REININGER AJ et al.: Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb. Haemost. (1994) 72:912–918.
   PubMed Web of Science ®Google Scholar
• ASSALEY J, BARON JM, CIBILS LA: Effects of magnesium sulfate infusion upon clotting parameters in patients with pre-eclampsia. J. Perinat. Med. (1998) 26:115–119.
   PubMed Web of Science ®Google Scholar
• RHEE E, JAMES A, WALKER C et al.: Maternal and fetal platelet function after maternal exposure to Mg504.Obstet.Cynecol. (2001) 185:S151.
   Google Scholar
• LEE K-S, MITTENDORF R, BESINGER RE et al.: Mechanisms of mortality in the Magnesium and Neurologic Endpoints Trial (MagNET Trial): Papile grade III neonatal intraventricular hemorrhage. Pediatr. Res. (2002) 51:411A.
   Web of Science ®Google Scholar
• SCHENDEL DE, BERG CJ, YEARGIN-ALLSOPP M et al: Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA (1996) 276: 1805-1810.
   Google Scholar
• CROWTHER CA, HILLER JE, DOYLE LW et al.: Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled JAMA (2003) 290:2669–2676.
   Google Scholar
• BISHOP EH, WOUTERSZ TB: Isoxsuprine, a myometrial relaxant. Obstet. Cynecol. (1961) 17:442–446.
   Web of Science ®Google Scholar
• HENDRICKS CH, CIBILS LA, POSE SV et al.: The pharmacologic control of excessive uterine activity with isoxsuprine. Am. J. Obstet. Cynecol. (1961) 82:1064–1078.
   PubMed Web of Science ®Google Scholar
• FDA: Ritodrine approved for premature labor: FDA. Drug Bull. (1980) 10:22–23.
   Google Scholar
• CARSTEN ME, MILLER JD: A new look at uterine muscle contraction. km Obstet. Cynecol. (1987) 157:1303–1315.
   PubMed Web of Science ®Google Scholar
• SCHEID CR, HONEYMAN TW, FAY FS: Mechanism of beta-adrenergic relaxation of smooth muscle. Nature (1979) 277:32–36.
   PubMed Web of Science ®Google Scholar
• BERG G, ANDERSSON RG, RYDEN G: Beta-adrenergic receptors in human myometrium during pregnancy: changes in the number of receptors after beta-mimetic treatment. km Obstet. Cynecol. (1985) 151:392–396.
   PubMed Web of Science ®Google Scholar
• CARITIS SN, CHIAO JP, MOORE JJ et al.: Myometrial desensitization after ritodrine infusion. Am. J. Physiol. (1987) 253:E410–E417.
   PubMed Web of Science ®Google Scholar
• KING JF, GRANT A, KEIRSE MJ et al.:Beta-mimetics in preterm labour: an overview of the randomized controlled trials. BIOC (1988) 95:211–222.
   Google Scholar
• CANADIAN PRETERM LABOR INVESTIGATION GROUP: Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N. Engl. J. Med. (1992) 327:308–312.
   PubMed Web of Science ®Google Scholar
• MACONES GA, BERLIN M, BERLIN JA: Efficacy of oral beta-agonist maintenance therapy in preterm labor: a meta-analysis. Obstet. Cynecol (1995) 85:313–317.
   Web of Science ®Google Scholar
• HANKINS GD: Complications of beta-sympathomimetic tocolytic agents. In: Critical Care Obstetrics. Clark SL, Cotton DB, Hankins GD, Phelan JP (Eds), Blackwell Scientific Publications, Boston, MA, USA (1991):223–250.
   Google Scholar
• GROSPIETSCH G, FENSKE M, GIRNDT J et al.: The renin-angiotensin-aldosterone system, antidiuretic hormone levels and water balance under tocolytic therapy with fenoterol and verapamil. Int. J. Cynaecol Obstet. (1980) 17:590–595.
   PubMedGoogle Scholar
• CANO A, TOVAR I, PARRILLA JJ et al:Metabolic disturbances during intravenous use of ritodrine: increased insulin levels and hypokalemia. Obstet. Cynecol (1985) 65:356–360.
   Web of Science ®Google Scholar
• ROSENE KA, FEATHERSTONE HJ, BENEDETTI TJ: Cerebral ischemia associated with parenteral terbutaline use in pregnant migraine patients. Am. J. Obstet. Cynecol (1982) 143:405–407.
   PubMed Web of Science ®Google Scholar
• LEVENO KJ, CUNNINGHAM FG: Beta-adrenergic agonists for preterm labor. N. Engl. J. Med. (1992) 327:349–351.
   PubMed Web of Science ®Google Scholar
• MICHALAK D, KLEIN V, MARQUETTE GP: Myocardial ischemia: a complication of ritodrine tocolysis. Am. J. Obstet. Cynecol (1983) 146:861–862.
   PubMed Web of Science ®Google Scholar
• FINLEY J, KATZ M, ROJAS-PEREZ M et al: Cardiovascular consequence of beta-agonist tocolysis: an echocardiographic study. Obstet. Cynecol (1984) 64:787–791.
   Web of Science ®Google Scholar
• NAIR GV, GHOSH AK, LEWIS BV: Bowel distention during treatment of premature labor with beta-receptor agonists. Lancet (1976) 1:907.
   PubMed Web of Science ®Google Scholar
• SHENKER L: Effect of isoxsuprine on fetal heart rate and fetal electrocardiogram. Obstet. Cynecol (1965) 26:104–109.
   Web of Science ®Google Scholar
• KATZ VL, SEEDS JW: Fetal and neonatal cardiovascular complications from beta-sympathomimetic therapy for tocolysis. Am. J. Obstet. Cynecol (1989) 161:1–4.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE FA, AERTS L: The effect of beta-sympathomimetics on the fetal endocrine pancreas. Eur. Obstet. Cynecol Reprod. Biol. (1983) 15:395–408.
   PubMedGoogle Scholar
• LEAKE RD, HOBEL CJ, OKADA DM et al.: Neonatal metabolic effects of oral ritodrine hydrochloride administration. Pediatr Pharmacol (1983) 3:101–106.
   PubMedGoogle Scholar
• BRAZY JE, PUPKIN MJ: Effects of maternal isoxsuprine administration on preterm infants. J. Pediatr. (1979) 94:444–448.
   PubMed Web of Science ®Google Scholar
• GROOME LJ, GOLDENBERG RL, CLIVER SP et al.: Neonatal periventricular-intraventricular hemorrhage after maternal beta-sympathomimetic tocolysis. The March of Dimes Multicenter Study Group. Am. J. Obstet. Cynecol (1992) 167:873–879.
   PubMed Web of Science ®Google Scholar
• PRANIKOFF J, HELMCHEN R, EVERTSON L: Tocolytic therapy and intraventricular hemorrhage in the neonate. Am. J. Obstet. Cynecol (1991) 164:387.
   Google Scholar
• OZCAN T, TURAN C, EKICI E et al: Ritodrine tocolysis and neonatal intraventricular-periventricular hemorrhage. Cynecol Obstet. Invest. (1995) 39:60–62.
   PubMed Web of Science ®Google Scholar
• FREYSZ H, WILLARD D, LEHR A et al: A long term evaluation of infants who received a beta-mimetic drug while in utero. Perinat. Med. (1977) 5:94–99.
   PubMed Web of Science ®Google Scholar
• KARLSSON K, KRANTZ M, HAMBERGER L: Comparison of various betamimetics on preterm labor, survival and development of the child. J. Perinat. Med. (1980) 8:19–26.
   PubMed Web of Science ®Google Scholar
• SVENNINGSEN NW: Follow-up studies on preterm infants after maternal beta-receptor agonist treatment. Acta Obstet. Cynecol Scand. Suppl (1982) 108:67–70.
   PubMedGoogle Scholar
• ZUCKERMAN H, REISS U, RUBINSTEIN I: Inhibition of human premature labor by indomethacin. Obstet. Cynecol (1974) 44:787–792.
   Web of Science ®Google Scholar
• MACONES GA, MARDER SJ, CLOTHIER B et al: The controversy surrounding indomethacin for tocolysis. Am. J. Obstet. Cynecol (2001) 184:262–272.
   Google Scholar
• HANNAH ME: Search for best tocolyticfor preterm labor. Lancet (2000) 356:699–700.
   PubMed Web of Science ®Google Scholar
• MACONES GA, ROBINSON CA: Is there justification for using indomethacinin preterm labor? An analysis of neonatal risks and benefits. Am. J. Obstet. Cynecol (1997) 177:819–824.
   PubMed Web of Science ®Google Scholar
• GORDON MC, SAMUELS P: Indomethacin. Clin. Obstet. Cynecol (1995) 38:697–705.
   PubMed Web of Science ®Google Scholar
• ZUCKERMAN H, SHALEV E, GILAD G et al.: Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. J. Perinat. Med. (1984) 12:25–29.
   PubMed Web of Science ®Google Scholar
• PANTER KR, HANNAH ME, AMANKWAH KS et al.: The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. BIOC (1999) 106:467–473.
   Google Scholar
• MORALES WJ, MADHAV H: Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am. J. Obstet. Cynecol (1993) 169:97–102.
   PubMed Web of Science ®Google Scholar
• MORALES WJ, SMITH SG, ANGEL JLet al.: Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study. Obstet. Cynecol (1989) 74:567–572.
   Google Scholar
• BESINGER RE, NIEBYL JR, KEYES WG et al.: Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am. J. Obstet. Cynecol (1991) 164:981–988.
   PubMed Web of Science ®Google Scholar
• GYETVAI K, HANNAH MR, HODNETT ED et al.: Tocolytics for preterm labor: a systematic review. Obstet. Cynecol (1999) 94:869–877.
   Web of Science ®Google Scholar
• KEIRSE MH: Indomethacin tocolysis in preterm labour. In: Pregnancy and Child-birth module of the Cochrane Database of Systematic Reviews. Enkin M, Keirse M, Renfrew M, Neilson J (Eds), BMJ Publishing Group, London (1995).
   Google Scholar
• REPKE JT, NIEBYL JR: Role of prostaglandin synthetase inhibitors in the treatment of preterm labor. Semin. Reprod. Endocrinol (1985) 3:259–272.
   Google Scholar
• STEIGER RM, BOYD EL, POWERS DR et al.: Acute maternal renal insufficiency in premature labor treated with indomethacin. Am. J. Perinatol (1993) 10:381–383.
   PubMed Web of Science ®Google Scholar
• GALLER M, FOLKERT VW, SCLONDORFF D: Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA (1981) 246:154–155.
   PubMed Web of Science ®Google Scholar
• LUNT CC, SATIN AJ, BARTH WH Jr et al.: The effect of indomethacin tocolysis on maternal coagulation status. Obstet. Cynecol (1994) 84:820–822.
   Google Scholar
• DURANDY A, BRAMI C, GRISCELLI C: The effects of indomethacin administration during pregnancy on women's and newborns' T-suppressor lymphocyte activity and on HLA Class II expression by newborns' leukocytes. Am. J. Reprod. Immunol (1985) 8:94–100.
   Web of Science ®Google Scholar
• CANTOR B, TYLER T, NELSON RM et al.: Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors. ./. Reprod. Med. (1980) 24:240–223.
   Google Scholar
• MART G, MOISE KJ Jr, DETER RL et al: Doppler assessment of the renal blood flow velocity waveform during indomethacin therapy for preterm labor and polyhydramnios. Obstet. Cynecol. (1990) 75:199–201.
   Web of Science ®Google Scholar
• WIGGINS DA, ELLIOT JP: Oligohydramnios in each sac of a triplet gestation caused by Motrin-fulfilling Kock's postulates. Am. Obstet. Cynecol. (1990) 162:460–461.
   PubMed Web of Science ®Google Scholar
• GLOOR JM, MUCHANT DG, NORLING LL: Prenatal maternal indomethacin use resulting in prolonged neonatal renal insufficiency. J. Perinatol (1993) 13:425–427.
   PubMedGoogle Scholar
• NIEBYL JR, WITTER FR: Neonatal outcome after indomethacin treatment for preterm labor. Am. I. Obstet. Cynecol (1986) 155:747–749.
   PubMed Web of Science ®Google Scholar
• MOISE KJ Jr: Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am. I. Obstet. Cynecol (1993) 168:1350–1353.
   PubMed Web of Science ®Google Scholar
• MOISE KJ Jr, HUHTA JC, SHARIF DS et al.: Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Eng]. J. Med. (1988) 319:327–331.
   PubMed Web of Science ®Google Scholar
• HUHTA JC, MOISE KJ, FISHER DJ et al.: Detection and quantitation of constriction of the fetal ductus arteriosus by Doppler echocardiography. Circulation (1987) 75:406–412.
   PubMed Web of Science ®Google Scholar
• SAENGER JS, MAYER DC, D'ANGELO LJ et al: Ductus-dependent fetal cardiac defects contraindicate indomethacin tocolysis. ./. Perinatol (1992) 12:41–47.
   PubMedGoogle Scholar
• MANCHESTER D, MAROLIS HS, SHELDON RE: Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am. J. Obstet. Cynecol (1976) 126:467–469.
   PubMed Web of Science ®Google Scholar
• LEVIN DL, FIXLER DE, MORRISS FC et al: Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J. Pediatr. (1978) 92:478–483.
   PubMed Web of Science ®Google Scholar
• NORTON ME, MERRILL J, COOPER BA et al: Neonatal complications after the administration of indomethacin for preterm labor. N Engl. J. Med. (1993) 329:1602–1607.
   PubMed Web of Science ®Google Scholar
• KATZ Z, LANCET M, YEMINI M et al: Treatment of premature labor contractions with combined ritodrine and indomethacin. Int.j Cynaecol. Obstet. (1983) 21:337–342.
   PubMed Web of Science ®Google Scholar
• MARPEAU L, BOUILLIE J, BARRAT J et al.: Obstetrical advantages and perinatal risks of indomethacin: a report of 818 cases. Fetal Diagn. Ther. (1994) 9:110–115.
   PubMed Web of Science ®Google Scholar
• NORTON M, MERILL J, COOPER B et al: Neonatal complications after the administration of indomethacin for preterm labor. N Engl. J. Med. (1993) 329:1602–1607.
   PubMed Web of Science ®Google Scholar
• ERONEN M, PESONEN E, KURKI T et al: Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterrm labor. ./. Pediatr: (1994) 124:782–788.
   PubMed Web of Science ®Google Scholar
• GARDNER MO, OWEN J, SKELLY S et al.: Preterm delivery and indomethacin: a risk factor for neonatal complications? Reprod. Med. (1996) 41:903–906.
   Web of Science ®Google Scholar
• VERMILLION ST, NEWMAN RB: Recent indomethacin tocolysis is not associated with neonatal complications in preterm infants. Am. I. Obstet. Cynecol. (1999) 181:1083–1086.
   PubMed Web of Science ®Google Scholar
• NUKI G: Non-steroidal analgesic and anti-inflammatory agents. BE Med. I (1983) 287:39–43.
   PubMed Web of Science ®Google Scholar
• BUNNING RD, BARTH WF: Sulindac: a potentially renal-sparing nonsteroidal anti-inflammatory drug. "AMA (1982) 248:2864–2867.
   PubMed Web of Science ®Google Scholar
• KRAMER WB, SAADE G, OU CN et al.:Placental transfer of sulindac and its active sulfide metabolite in humans. Am. I. Obstet. Cynecol. (1995) 172:886–890.
   PubMed Web of Science ®Google Scholar
• RASANEN J, JOUPPILA P: Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study. Am. Obstet. Cynecol. (1995) 173:20–25.
   PubMed Web of Science ®Google Scholar
• KRAMER WB, SAADE GR, BELFORT M et al.: A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor. Aid Obstet. Cynecol. (1999) 180:396–401.
   PubMed Web of Science ®Google Scholar
• CLYMAN RI, HARDY P, WALEHN et al.:Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am. Physic] (1999) 276:R913–R921.
   PubMed Web of Science ®Google Scholar
• LOCATELLI A, VERGANI P, BELLINI P et al.: Can a cylooxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin? 13.10C (2001) 108:325-326.
   Google Scholar
• MACONES GA, ROBINSON CA: Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Aid I Obstet. Cynecol (1997) 177:819–824.
   PubMed Web of Science ®Google Scholar
• ULMSTEN W, ANDERSSON KE, WINGERUP L: Treatment of premature labor with the calcium antagonist nifedipine. Arch. Cynecol. (1980) 229:1–5.
   PubMedGoogle Scholar
• BRAUNWALD E: Mechanism of action of calcium-channel-blocking agents. N Engl. [Med (1982) 307:1618–1627.
   PubMed Web of Science ®Google Scholar
• READ MD, WELLBY DE: The use of calcium antagonist (nifedipine) to suppress preterm labour. 13.10C (1986) 93:933–937.
   Google Scholar
• PAPATSONIS DN, VAN GEIJN HP, ADER HJ et al.: Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet. Cynecol. (1997) 90:230–234.
   Web of Science ®Google Scholar
• PAPATSONIS DN, KOK JH, VAN GEIJN HP et al.: Neonatal effects of nifedipine and ritodrine for preterm labor. Obstet. Cynecol. (2000) 95:477–481.
   Google Scholar
• KING JF, FLENADY VJ, PAPATSONIS DN, DEKKER GA, CARBONNE B: Calcium channel blockers for inhibiting preterm labor. Cochrane Database Syst. Rev (2003) 1:CD002255.
   Google Scholar
• •This 2003 update of a 2002 systematic literature review and meta-analysis evaluated all published and unpublished RCTs evaluating calcium channel blocker (mainly nifedipine) tocolysis between 20 and 36 weeks of gestation. The analysis includes 11 trials (comprising a total of 870 women).
   Google Scholar
• CAUVIN C, LOUTZENHISER R, VAN BREEMEN C: Mechanisms of calcium antagonist-induced vasodilation. Al11711. Rev Pharmacol Toxicol. (1983) 23:373–396.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Hypotension and coronary events on nifedipine: reassessing nifedipine safety. Prescrire Int. (1998) 7:90–91.
   PubMedGoogle Scholar
• FISCHBERG GM, LOZANO E, RAJAMANI K et al: Stroke precipitated by moderate blood pressure reduction. Emerg. Med. (2000) 19:339–346.
   Web of Science ®Google Scholar
• AHR HJ, BOMHARD E, MAGER E et al.: Calcium channel blockers and cancer: is there preclinical evidence for an association? Cardiol (1997) 88:68–72.
   Google Scholar
• DAVIS WB, WELLS SR, KULLER JA et al: Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. Obstet. Gynecol Surv. (1997) 52:198–201.
   PubMedGoogle Scholar
• OEI SG, OEI SK, BROLMANN HA: Myocardial infarction during nifedipine therapy for preterm labor. N Engl. J. Med.(1999) 340:154.
   PubMed Web of Science ®Google Scholar
• SNYDER SW, CARDWELL MS: Neuromuscular blockade with magnesium sulfate and nifedipine. Am. I. Obstet. Gynecol (1989) 161:35–36.
   PubMed Web of Science ®Google Scholar
• JAMS J: Preterm birth. In: Obstetrics: Normal and Problem Pregnancies.Gabbe SG, Niebyl JR, Simpson JL (Eds), Churchill Livingstone, New York (1996)743–820.
   Google Scholar
• PARISI VM, SALINAS J, STOCKMAR EJ: Fetal vascular response to maternal nicardipine administration in the hypertensive ewe. Am. J. Obstet. Gynecol (1989) 161:1035–1039.
   PubMed Web of Science ®Google Scholar
• MARI G, KIRSHON B, MOISE KH Jr et al.: Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Am. Obstet. Gynecol (1989) 161:1514–1518.
   Google Scholar
• MELIN P, TROJNAR J, JOHANSSON B et al.: Synthetic antagonists of the myometrial response to vasopressin and oxytocin. Endocrinol (1986) 111:125–131.
   Web of Science ®Google Scholar
• AKERLUND M, STROMBERG P, HAUKSSON A et al.: Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. EIOG (1987) 94:1040–1044.
   Google Scholar
• MOUTQUIN JM, SHERMAN D, COHEN H et al.: Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am. J. Obstet. Gynecol (2000) 182:1191–1199.
   PubMed Web of Science ®Google Scholar
• THE WORLDWIDE ATOSIBAN VERSUS BETA-AGONISTS STUDY GROUP: Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. EIOG (2001) 108:133–142.
   Google Scholar
• GOODWIN TM, ZOGRABYAN A: Oxytocin receptor antagonists. Update. Perinatol (1998) 25:859–871.
   Google Scholar
• BOSSMAR T, AKERLUND M, FANTONI G et al.: Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of oxytocin receptor antagonist atosiban. Am. Obstet. Gynecol (1994) 171:1634–1642.
   PubMed Web of Science ®Google Scholar
• ROMERO R, SIBAI BM,SANCHEZ-RAMOS L et al.: An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obstet. Gynecol(2000) 182:1173–1183.
   Google Scholar